Evaluation of Disease Epidemiology, Comorbidities, Treatment Patterns, and Healthcare Resource Utilization of Alopecia Areata in United Arab Emirates: A Retrospective Claims Database Study
Author(s)
Al Hammadi A1, Farghaly M2, Al dallal S2, Zayed MWA3, Fadwa E3, Badarinath CR4, Mohamed H3
1DermaMed Clinic, Dubai, Dubai, United Arab Emirates, 2Dubai Health Authority, Dubai, Dubai, United Arab Emirates, 3Pfizer Inc Ltd, Dubai, Dubai, United Arab Emirates, 4Senior Consultant, Real-World Evidence, IQVIA, Dubai, United Arab Emirates
Presentation Documents
OBJECTIVES: Alopecia areata (AA) is an autoimmune disorder that impacts approximately 2% of population globally with substantial psychological and economic burden. The current study assessed the disease burden, comorbidities, treatment patterns, and specialties involved in AA diagnosis, with special emphasis on the HCRU of associated comorbidities in patients with AA in Dubai, United Arab Emirates (UAE).
METHODS: This retrospective longitudinal secondary data study using Dubai Real-World Database (DRWD) was conducted from 01 January 2014 to 30 June 2022. Patients with at least one AA diagnosis claim during the index period (01 January 2015 to 30 June 2021) and having continuous enrolment of at least 12 months in the post-index period were analyzed. The patients were stratified into sub-cohorts based on the diagnosis code and treatment pattern into mild, moderate-to-severe, and others.
RESULTS: The study included 11,851 patients with AA (mean age: mild: 37 years; moderate-to-severe: 36 years), and with male predominance (mild: 77.6%; moderate-to-severe: 60.8%). The most prevalent comorbid autoimmune disorders in moderate-to-severe AA sub-cohort were contact dermatitis and eczema (62.1%), atopic dermatitis (36.1%) and asthma (36.1%). Most patients consulted dermatologists for treatment advice (mild AA: 87.4%; moderate-to-severe AA: 29.5%) and notably within one day of AA diagnosis. During 12-month post-index period, topical steroids was frequently prescribed drug across cohorts, regardless of disease severity. Analysis of comorbidities among AA patients indicated additional significant HCRU burden among these subsets of patients. The median disease-specific HCRU was higher for psychological comorbidities versus autoimmune comorbidities (USD 224.99 vs USD 103.70).
CONCLUSIONS: The study reports substantial disease and cost burden due to associated autoimmune and psychological comorbidities in patients with mild and moderate-to-severe AA. Study highlights need for better intervention in the treatment of AA that may help reduce disease and cost burden.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
SA28
Topic
Economic Evaluation, Real World Data & Information Systems, Study Approaches
Topic Subcategory
Health & Insurance Records Systems
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)